Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder

Urological Research

Volumn 26, Issue 4, 1998, Pages 235-241

  Li, Benyi ^a   Kanamaru, Hiroshi ^a   Noriki, Sakon ^a   Yamaguchi, Tadanori ^b   Fukuda, Masaru ^a   Okada, Kenichiro ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b Medical Laboratory Division   (Japan)

Author keywords

bcl 2; Bladder cancer; Immunohistochemistry; p53; Urothelial dysplasia

Indexed keywords

ONCOPROTEIN;

ADULT; AGED; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER SURVIVAL; DIAGNOSTIC VALUE; EPITHELIUM DYSPLASIA; FEMALE; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UROTHELIUM;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; FEMALE; GENE EXPRESSION; GENES, BCL-2; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 0031666485     PISSN: 03005623     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002400050051     Document Type: Article

References (19)

1. Bihm V, Tomita Y, Kawasaki T, Katagiri A, Imat T, Takeda M, Takahashi K (1996) Prognostic value of bcl-2 and p53 expression in urinary tract transitional cell cancer. J Natl Cancer Res 88:686
2. Furihata M, Sonobe H, Ohtsuki Y, Yamashita M, Morioka M, Yamamoto A, Terao N, Kuwahara M, Fujisaki N (1996) Detection of p53 and bcl-2 protein in carcinoma of the renal pelvis and ureter including dysplasia. J Pathol 178:133
3. Glick SH, Howell LP, White RWD (1996) Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. J Urol 155:1754
4. Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM (1994) Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 54:2095
5. Hamsel BT, Smedts F, Kuijpers J, Jeunink M, Trimbos B, Ramaekers F (1996) Bcl-2 immunoreactivity increases with severity of CIN: a study of normal cervical epithelial, CIN, and cervical carcinoma. J Pathol 179:26
6. Kakizoe T, Matumoto K, Nishio Y, Ohtani M, Kishi K. (1985) Significance of carcinoma in situ and dysplasia in association with bladder cancer. J Urol 133:395
7. Kaklamanis L, Savage A, Mortensen N, Tsiotos P, Doussis-Anagnostopoulou I, Biddolph S, Whitehouse R, Harris AL, Gatter KC (1996) Early expression of bcl-2 protein in the adenoma-carcinoma sequence of colorectal neoplasia. J Pathol 179:10
8. Koroltchouk V, Stanley K, Stjernsward J, Mott K (1987) Bladder cancer: approaches to prevention and control. Bull WHO 65:513
9. Lauwers GY, Scott GV, Hendricks J (1994) Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 73:2900
10. Miyashita T, Krajewski S, Krejewski M (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799
11. Murphy WM, Soloway MS (1982) Urothelial dysplasia. J Urol 127:849
12. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 94:23
13. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ (1990) Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602
14. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY (1990) Expression of the bcl-2 oncogene protein is not specific for the 14:18 Chromosomal translocation. Am J Pathol 137:225
15. Pollina L, Pacini F, Fontanini G, Vignati S, Bevilacqua G, Basolo F (1996) Bcl-2, p53 and proliferating cell nuclear antigen expression is related to the degree of differentiation in thyroid carcinomas. Br J Cancer 73:139
16. Sanchez de la Muela P, Rosell D, Aguera L, de Castro F, Isa W, Robles JE, Zudaire JJ, Berian JM (1993) Multivariate analysis of progression in superficial bladder cancer. Br J Urol 71:284
17. Vojtesek B, Bartek J, Midgley CA, Lane DP (1992) An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 151:237
18. Wang Y, Szekely L, Okan I, Klein G, Wiman KG (1993) Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8:3427
19. Watson AJM, Merritt AJ, Jones LS, Askew JN, Anderson E, Becclolini A, Balzi M, Potten CS, Hickman JA (1996) Evidence for reciprocity of bcl-2 and p53 expression in human colorectal adenomas and carcinomas. Br J Cancer 73:889